Connect Biopharma Holdings Long Term Debt 2021-2024 | CNTB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Connect Biopharma Holdings long term debt from 2021 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Connect Biopharma Holdings long term debt from 2021 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.8B
Regeneron Pharmaceuticals (REGN)	$126.4B
Vertex Pharmaceuticals (VRTX)	$124.2B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$100.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$88.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.2B
BioNTech SE (BNTX)	$29.7B
Biogen (BIIB)	$28.9B
Moderna (MRNA)	$27.7B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.4B
Vaxcyte (PCVX)	$13B
Incyte (INCY)	$12.8B
Insmed (INSM)	$12.6B
Exact Sciences (EXAS)	$12.6B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.9B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.5B
Intra-Cellular Therapies (ITCI)	$7.9B
Exelixis (EXEL)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B